01 “5G+ Smart Healthcare Application Pilot Project” of Sichuan Cancer Hospital Honored as National Outstanding Project after Passing the Acceptance Evaluation
The 5G+ Smart Healthcare Application Pilot Project—Smart Radiotherapy Cloud Platform”, applied by Sichuan Cancer Hospital (SCH), has successfully passed the acceptance evaluation and was honored as National Outstanding Project.
Since 2020, SCH has pioneered a model that integrates 5G medical private networks, edge cloud computing, and tumor imaging AI contouring. This innovative approach has enabled seamless inter-hospital data connectivity and introduced the FCN-based deep learning model to achieve precise AI-driven tumor delineation and generate remote radiotherapy treatment plans.
The platform has, since its inception, significantly eased the bottleneck of remote operations involving large-volume radiotherapy imaging data.
02 Research Results on Esophageal Cancer Surgery by Department of Thoracic Surgery Published in Top Journal JTCVS
The latest research results by Professor Han Yongtao’s team from the Department of Thoracic Surgery, titled “Long-term outcomes of intrathoracic vs. cervical anastomosis post-esophagectomy: a large-scale propensity score matching analysis”, has been published online in The Journal of Thoracic and Cardiovascular Surgery (JTCVS), the top-ranked journal in the field of thoracic and cardiovascular surgery and the official journal of the American Association for Thoracic Surgery (AATS). JTCVS is classified as a Q1 journal in the Medicine/Surgery category by the Chinese Academy of Sciences.
This research is a large-scale, retrospective, propensity score matching analysis that focuses on the long-term survival outcomes of patients with esophageal squamous cell carcinoma who underwent radical esophagectomy, comparing two surgical approaches: cervical anastomosis (McKeown procedure) and intrathoracic anastomosis (Ivor-Lewis procedure).
03 SCH Appointed as Chair Institution of the First Committee of the Clinical Biospecimen and Data Management Branch of Sichuan Preventive Medicine Association
On January 4, the inaugural election meeting of the First Committee of the Clinical Biospecimen and Data Management Branch of the Sichuan Preventive Medicine Association, along with the Academic Conference on the Application and Translation of Biospecimens and Clinical Big Data, was successfully held in Chengdu.
Professor Cao Bangrong from SCH was elected as Chair, and Professor Leng Xuefeng was elected as Vice Chair. Committee members are from all 21 cities and prefectures of Sichuan Province.
04 Department of Ultrasound Recognized as Outstanding Contributor to Thyroid Ablation Technical Training in 2024
On January 11, at the 2025 Working Meeting of the Thyroid Disease Expert Panel under the Interventional Medicine Expert Committee of the Center for Capacity Building and Continuing Education, National Health Commission, the Department of Ultrasound of SCH was recognized as Outstanding Contributor in 2024 for its role as the Thyroid Ablation Technical Training Base.
Professor Lu Man, Director of the training base, received the Outstanding Contribution Award under the program for enhancing precision capacity in minimally invasive intervention at county-level medical institutions.
05 SCH Successfully Performs First PICC Placement Using Magnetic Tracking Technology in Western China
On January 14, the Catheterization Lab of the Vascular Access Center of SCH successfully performed the first peripherally inserted central catheter (PICC) placement in Western China utilizing magnetic tracking technology combined with intracavitary electrocardiographic (IC-ECG) technology for real-time tip navigation and positioning.
In oncology treatment, PICC is a commonly used intravenous access method that avoids irritation of peripheral veins by chemotherapeutic agents and helps reduce patient discomfort. The newly introduced magnetic tracking system in SCH serves as a “precise navigator” for PICC placement, significantly improving the accuracy and success rate of the placement.
06 Core Members of the Gynecologic Oncology MDT Appointed to Key Academic Positions in Various Subcommittees of the Chinese Medical Doctor Association’s Minimally Invasive and Noninvasive Medicine Committee
The Second Plenary Session of the Third Committee of the Minimally Invasive and Noninvasive Medicine Committee of the Chinese Medical Doctor Association (CMDA) was successfully held in Nanjing.
Zhang Guonan, Vice Chair of the CMDA Minimally Invasive and Noninvasive Medicine Committee and Chief Expert of the Gynecologic Oncology MDT at SCH, was appointed as Chair of the Gynecologic Oncology Subcommittee. Wang Dengfeng was appointed as Vice Chair of the Youth Working Group. Liu Aixiang was appointed as a member of the Hepatobiliary Surgery Subcommittee. Zhou Haiyang was appointed as a member of the Colorectal Surgery Subcommittee. Xu Jia was appointed as a member of the Breast Surgery Subcommittee. Xiao Shuomeng was appointed as a member of the Gastrointestinal Subcommittee. Peng Liping was appointed as a member and Secretary of the Gynecologic Oncology Subcommittee.
07 Important Research Results on TTS after Neoadjuvant Chemoradiotherapy for Esophageal Cancer on International Journals by Chief Physician Peng Lin and Chief Physician Wang Qifeng’s Teams of the Department of Thoracic Surgery
Recently, two important research articles by the teams of Dr. Peng Lin, Chief Physician of the Department of Thoracic Surgery, and Dr. Wang Qifeng, Chief Physician of the Department of Radiation Oncology, were consecutively published in Annals of Surgical Oncology, an international prestigious and authoritative journal. The two articles are: “Prognostic Impact of Sarcopenia and Surgical Timing in Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Chemoradiotherapy: TIMES Study” and “Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer after Neoadjuvant Chemoradiotherapy: A Retrospective Study”.
This research focuses on optimizing Time to Surgery (TTS) after neoadjuvant chemoradiotherapy for esophageal cancer and provides important evidence-based support for clinical decision-making.
08 Pneumatic Logistics and Intelligent Robots Officially Launched in Tianfu Campus, Ushering in a New Era of Smart Medical Supply Transport
Tianfu Campus of SCH has introduced a pneumatic logistics and intelligent delivery robot system, establishing a smart internal transport network for pharmaceuticals, specimens, and emergency supplies. This marks a new phase of intelligent development in the hospital’s logistics management.
09 Project by Department of Head and Neck Surgery Approved for 2024 Medical AI Clinical Application Research Program by National Institute of Hospital Administration of the National Health Commission
To promote innovative applications of AI in the medical field, the National Institute of Hospital Administration of the National Health Commission has launched the 2024 “Medical AI Clinical Application Research Program”, aiming to lead innovative breakthroughs and wide adoption of medical AI. The project titled “Research on an AI-Based Intelligent Service Platform for Thyroid Nodules” submitted by Professor Li Chao’s team from SCH has been successfully approved.
10 SCH Successfully Implements Integrated Treatment for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Integrated treatment for Chemotherapy-Induced Peripheral Neuropathy (CIPN) refers to a comprehensive therapeutic approach targeting peripheral neuropathy caused by chemotherapy drugs. Neuropathy, commonly seen after treatments with platinum-based or taxane drugs, results in a series of neurological dysfunction symptoms and signs. The highlight of the integrated treatment lies in its multidisciplinary approach: combining pharmacological therapy, physical prevention, traditional Chinese medicine, and minimally invasive interventional therapies to deliver personalized treatment plans for different symptoms and stages of CIPN. SCH has successfully implemented this new CIPN treatment technology, completing 14 cases to date, with patients reporting significant symptom improvement.
11 Focusing on Cancer Pain Management: SCH Provides Home-Based Extended Nursing Services
Cancer pain can be extremely distressing for patients undergoing treatment. Intrathecal analgesic pump implantation is an advanced pain management technique, yet its maintenance requires regular professional evaluation. To address patient needs and mobility challenges, SCH has launched a home-based maintenance service for intrathecal analgesic pumps. On the afternoon of February 26, SCH’s pain management team successfully provided the service to Mr. Zhang, a patient suffering from long-term cancer pain.
12 SCH Launches 2025 Clinical Nurse Specialist Training Program
On March 3, the 2025 Spring Practice Nurse Training Program officially commenced, with 133 participants enrolled. SCH has developed a precise, systematic, and comprehensive training system based on the core competencies of practice nurses. Currently, SCH hosts two clinical practice teaching bases recognized by the Chinese Nursing Association in nutrition and oncology, along with six provincial-level training bases. Since 2010, 27 training sessions have been held, training a total of 2,333 practice nurses, covering 25 provinces, municipalities, and autonomous regions.
13 Pediatric Oncology Team Treats Rare Intracranial Tumor in a 14-Year-Old Boy
Recently, following a multidisciplinary consultation and in accordance with guidelines from the International Society of Pediatric Oncology (SIOP), the Department of Pediatric Oncology developed a personalized chemotherapy plan for a 14-year-old boy diagnosed with intracranial germ cell tumor. After four cycles of treatment, the patient’s MRI on March 5 showed a significant reduction in tumor size, noticeable clinical improvement, and normalization of tumor markers—offering renewed hope for the young patient.
14 Multidisciplinary Team Successfully Removes Giant Thymic Carcinoma at Cervicothoracic Junction
On March 4, Professor Fang Qiang’s team from the Department of Thoracic Surgery, in collaboration with Professor Wang Shaoxin’s team from the Department of Head and Neck Surgery, successfully performed a radical resection on a patient with a giant anterior superior mediastinal mass spanning the cervicothoracic junction, who had previously sought treatment at various hospitals across China. CT imaging revealed a 5.3×5.6×6.9 cm mass. Biopsy indicated squamous cell carcinoma of thymic origin. Due to the tumor’s proximity to major mediastinal and cervical vessels, the trachea, and the recurrent laryngeal nerve, the surgery posed high risks. After six hours of multidisciplinary effort, the tumor was successfully and completely removed.
15 Surgical Team Establishes Presence in Tianfu Campus and Completes First Surgery
On March 17, SCH’s Surgical Ward I (Thoracic Surgery/Head and Neck Surgery), Department of Anesthesiology, and Intensive Care Unit officially established presence in the Tianfu Campus and began operations. On the same day, the departments successfully completed their first surgery, marking a significant milestone in the development of surgical services at the Tianfu Campus.
16 Hong Kong Hospital Authority Delegation Visits SCH
On March 17, a delegation led by Tony KO Pat-sing, Chief Executive of the Hong Kong Hospital Authority, visited SCH. The delegation toured the Tianfu Campus Outpatient Department, Proton Therapy Center, Traditional Chinese Medicine Treatment Area, and Daytime Treatment Center. SCH introduced its layout and service processes, the construction and advantages of the Proton Therapy Center, and innovative practices in integrative oncology and daytime treatment services. The delegation highly praised SCH’s comprehensive strength in cancer care.
17 SCH Rated Top Tier in Performance Monitoring of National Tertiary Public Cancer Speciality Hospitals
On March 18, the National Health Commission released the latest results of performance monitoring for tertiary public hospitals. SCH was rated A, the highest tier among cancer specialty hospitals. Starting this year, performance evaluation has been renamed as performance monitoring, with no public hospital rankings released—only the rating tiers are provided. Compared with the previous year, most of SCH’s indicators have improved, and its Case Mix Index (CMI) increased to 1.27 (from 1.15 last year).
18 SCH Contributes to Innovative Multi-Center Study Published in Top International Journal
On March 19, results from a multicenter collaborative study involving eight regional esophageal cancer treatment centers in China were officially published in JAMA Surgery—a No.1 international surgical journal with an impact factor of 15.9. The study, titled “Comparative Study of Neoadjuvant Strategies in Locally Advanced Esophageal Squamous Cell Carcinoma”, analyzed data from 1,622 patients in a real-world setting. It systematically compared the clinical efficacy of neoadjuvant chemotherapy plus immunotherapy versus standard neoadjuvant chemoradiotherapy, providing high-level evidence-based support for global precision treatment of esophageal cancer. The research was jointly completed by eight high-volume centers in China. Professor Li Zhigang of Shanghai Chest Hospital and Professor Leng Xuefeng of SCH served as co-corresponding authors.
19 Research Teams of Professors Zhang Guonan and Professor Huang Jianming on Gynecologic Oncology Achieve New Breakthroughs in Ovarian Cancer Drug Resistance
Recently, the gynecologic oncology research teams led by Professor Zhang Guonan and Professor Huang Jianming published two significant findings in iScience (a Cell Press journal) and Molecular Cancer Therapeutics (an AACR journal). These studies address challenges of low response rates to immune checkpoint blockade (ICB) therapy and resistance to PARP inhibitors (PARPi) in ovarian cancer. The first study found that amitriptyline restores ICB sensitivity by regulating the tryptophan metabolism–immune checkpoint axis and reshaping the immunosuppressive microenvironment. The second study demonstrated that all-trans retinoic acid (ATRA) reverses PARPi resistance induced by platinum-based chemotherapy by modulating relevant molecular phenotypes.
20 Animal Research Facility Successfully Accepted, Enhancing SCH’s Research Platform
On March 26, SCH’s new animal research center successfully passed the official acceptance evaluation. The facility will provide a high-quality environment for experimental animal studies and significantly strengthen SCH’s scientific research platform. It will also promote interdisciplinary integration, accelerate the recruitment of top-tier faculty, and lay a solid foundation for SCH’s efforts to establish a National Regional Cancer Medical Center and achieve major academic breakthroughs.
21 Thoracic Surgery Team Successfully Performs SCH’s First “Single-Port Thoracoscopic Sublobar Resection via Periareolar Hidden Incision”
Recently, the thoracic surgery team successfully performed SCH’s first single-port thoracoscopic sublobar resection via a periareolar hidden incision on a 74-year-old patient. A small incision approximately 2 cm in length was made along the edge of the areola, through which the team utilized a single-port thoracoscope and instruments to release thoracic adhesions and cavity closure caused by the patient’s previous surgery. The pulmonary nodule was precisely localized and the corresponding sublobar segment was excised. Due to the incision’s placement at the areola and the use of intradermal suturing techniques, no visible scarring was left postoperatively, achieving the goals of maximum minimally invasive surgery and cosmetic excellence.
22 Chen Meihua’s Team from Department of Radiation Oncology Publishes in Leading International Oncology Journal
Recently, the team led by Chen Meihua, Deputy Chief Physician of the Department of Radiation Oncology (Radiotherapy Center), published a comprehensive review article in the leading international oncology journal, Journal of Hematology & Oncology (Q1 journal by the Chinese Academy of Sciences with an impact factor of 29.9). The article systematically elaborates on the pivotal role of cancer-associated fibroblasts (CAFs) in tumorigenesis, metastasis, and therapeutic resistance, while exploring strategies to target CAFs in cancer treatment. Attending Physician Jia Hongyuan and research intern Chen Xingmin share first authorship. The study offers a novel perspective for addressing the challenges of tumor drug resistance.
23 Multidisciplinary Team Successfully Performs Complex Tracheal Tumor Resection
Recently, the Department of Thoracic Surgery cooperated with the Department of Head and Neck Surgery to perform a highly complex radical surgery on a patient with a malignant tracheal tumor who had previously sought treatment at multiple institutions. The thoracic surgery team performed thoracotomy, meticulously dissected around major blood vessels to mobilize the distal trachea down to the carina, while the head and neck surgery team mobilized and freed the upper trachea, carefully preserving the closely adjacent recurrent laryngeal nerves. Once the diseased segment of the trachea was fully excised and intraoperative frozen sections confirmed negative margins, measurements revealed a defect length of three centimeters. Thanks to seamless teamwork, the surgical team successfully completed end-to-end tracheal anastomosis, with intraoperative blood loss limited to 200 milliliters. The millimeter-level life-saving operation lasted a total of four hours.
24 SCH Leads Major Public Welfare Campaign for National Anti-Cancer Week 2025 (Sichuan Station)
April 15–21 marked the 31st National Anti-Cancer Week, which is themed “Prevent Cancer Scientifically, Live a Healthy Life”. Under the leadership of Sichuan Provincial Bureau of Disease Prevention and Control, Sichuan Cancer Center (Sichuan Cancer Hospital) led a province-wide mobilization throughout April to organize a series of public education activities.
Within Sichuan Province, initiatives included jogging activities and landmark light-up events across cities. The first Anti-Cancer Science Popularization Competition was held, receiving 230 submissions from 84 medical and healthcare institutions across 20 prefecture-level cities and autonomous prefectures in Sichuan. Sichuan Cancer Center issued an advocacy call for coordinated anti-cancer awareness activities in all prefecture-level cities (autonomous prefectures), resulting in participation from over 162 medical and healthcare institutions and 30 anti-cancer organizations.
Throughout April, SCH, in alignment with the efforts of the Cancer Diagnosis and Treatment Quality Improvement Alliance of Sichuan Province, launched “Sichuan Cancer Public Welfare Tour across Seven Key Communities”. During the initiative, more than 200 authoritative experts were dispatched to 13 alliance institutions across 10 prefecture-level cities and autonomous prefectures. The initiative featured 13 thematic lectures, 20 multidisciplinary discussion sessions on complex cases, 14 teaching sessions on ward rounds, and 24 public science education and free consultation sessions. Additionally, public awareness of cancer prevention was raised through health education and free medical consultation services were provided to the public. These efforts significantly enhanced the diagnostic and treatment capabilities of grassroots healthcare institutions, thereby contributing to a tighter cancer prevention and control network.
25 Professor Lu Man’s Team Publishes Research in CAS Q1 Journal
Recently, Dr. Han Li from Professor Lu Man’s team and other authors published a research article titled “A tetrahedral DNA nanoplatform with ultrasound-triggered biomimetic nanocarriers for targeted siMCM2 delivery and reversal of imatinib resistance in gastrointestinal stromal tumors” in Chemical Engineering Journal (IF: 13.4), a Q1 journal by the Chinese Academy of Sciences. The article is one of the major outcomes of a project led by Professor Lu Man as part of 2022 General Program of the National Natural Science Foundation of China, titled “Study on Ultrasound-Controlled Nanobionic System for Targeted Regulation of MCM2 to Reverse IM Resistance in Gastrointestinal Stromal Tumors and its Mechanism” (Project No. 82272015).
26 Compilation of Chinese Expert Consensus on Thyroid Cancer Led by SCH Officially Published
Recently, “Expert Consensus on the Management of Postoperative Dyspnea following Thyroid Tumor Surgery”, an academic paper led by Professor Li Chao from SCH and co-authored over the course of nearly a year by more than 90 authoritative thyroid experts from 20 major medical institutions across China, was published online in the National Medical Journal of China.
The consensus provides highly practical clinical guidance and stands out for its professionalism, evidence-based support, and reading experience. It fills a critical gap in the management of postoperative dyspnea, one of common serious complications following thyroid surgery, and holds significant value for the quality control of thyroid surgery, efficient complication prevention, and other areas in China.
27 Empowering Oncology with Intelligence and Advancing Together against Cancer—7th Tianfu Oncology Conference Successfully Held in Chengdu
From April 25 to 26, the 7th Tianfu Oncology Conference was successfully held in Chengdu. The event was hosted by Sichuan Anti-Cancer Association, organized by the Affiliate Cancer Hospital of University of Electronic Science and Technology of China (also known as Sichuan Cancer Hospital or Sichuan Cancer Center), and co-organized by the Chinese Society of Oncology of the Chinese Medical Association, West China Society of Therapeutic and Radiation Oncology, and Cancer Diagnosis and Treatment Quality Improvement Alliance of Sichuan Province.
Themed “Empowering Oncology with Intelligence and Advancing Together against Cancer”, the conference featured lectures by prestigious academicians and 25 parallel sessions. It attracted a distinguished lineup of domestic and international experts, including Chinese Academy of Sciences (CAS) Member He Jie, CAS Member Dong Chen, and Chinese Academy of Engineering (CAE) Member Ding Jian, to explore central issues and key challenges in cancer diagnosis and treatment.
28 SCH Proton Therapy Center Inaugurated
On April 26, SCH Proton Therapy Center was inaugurated at the Opening Ceremony of the 7th Tianfu Oncology Conference. The inauguration marks the forthcoming clinical application of the first proton radiotherapy system in western China.
29 National Cancer Center Singapore and SCH Sign Memorandum of Cooperation
On April 27, National Cancer Center Singapore and SCH signed a memorandum of cooperation, which highlighted commitment of both institutions to strengthening cooperation in various areas, such as medical treatment, scientific research, talent development, and academic exchanges. The partnership aims to further enhance SCH’s international influence in oncological research and promote the advancement of cancer prevention and treatment technologies with joint efforts of both institutions.
30 Professor Lin Tongyu and Professor Hong Huangming’s Team from SCH Leads China’s Independent Development of EZH1/2 Inhibitor HH2853, Achieving Breakthrough in r/r PTCL Treatment
Recently, Professor Lin Tongyu and Professor Hong Huangming’s team from SCH, in collaboration with Sun Yat-sen University Cancer Center and other domestic institutions, published the research results of the phase Ib clinical trial of China’s independently developed EZH1/2 inhibitor HH2853 in the treatment of relapsed and/or refractory peripheral T-cell lymphoma (r/r PTCL) in the Journal of Hematology & Oncology, a top-tier academic journal in the field (double Q1 by the Chinese Academy of Sciences with an impact factor of 29.9).
The research was conducted simultaneously at 15 Chinese medical centers on 34 r/r PTCL patients. The inhibitor demonstrated promising efficacy across PTCL subtypes: it achieved an Overall Response Rate (ORR) of 67.6%, including 29.4% Complete Responses (CR), while maintaining a manageable toxicity. Therefore, it provides a new therapeutic option for r/r PTCL patients.
The research paper represents SCH’s highest-impact original research article published this year. Professor Lin Tongyu stands as the sole corresponding author, while Professor Hong Huangming from SCH, Dr. Chen Zegeng from Sun Yat-sen University Cancer Center, Professor Zhang Mingzhi from the First Affiliated Hospital of Zhengzhou University, and Professor Peng Zhigang from the First Affiliated Hospital of Guangxi Medical University share first authorship.
Additionally, the research was selected for oral presentation at 2023 American Society of Hematology (ASH) Annual Meeting & Exposition—the first oral presentation from SCH at ASH’s annual meeting—garnering attention from international community.
31 Department of Pharmacy Showcases Research Results at AACR Annual Meeting 2025
From April 25 to 30, the American Association for Cancer Research (AACR) Annual Meeting 2025 was held in Chicago, the United States. Research results by Xiao Hongtao’s team from the Department of Pharmacy were selected for poster presentation.
32 Department of Thoracic Surgery Receives International Recognition with Multiple Research Results
From May 2 to 5, the 105th Annual Meeting of the American Association for Thoracic Surgery (AATS) was held in Seattle. One research article by the Department of Thoracic Surgery was selected as a late breaking abstract and another for poster presentation.
Recently, the Perioperative Symptom Assessment for Lung Surgery (PSA-Lung), jointly developed by Professor Li Qiang’s team from the Department of Thoracic Surgery and Professor Shi Qiuling’s team (the CN-PRO team), officially signed an international copyright agreement with Copenhagen University Hospital in Denmark. This marks the first time a patient-reported outcome (PRO) measurement tool independently developed by China has entered the mainstream international medical system.
From May 14 to 17, the 33rd Annual Meeting of the Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS 2025) was successfully held in Singapore. One research article by the Department of Thoracic Surgery was selected for oral presentation.
On May 18, the 2nd East Asia Esophageal Cancer Forum was held at the National Cancer Center Hospital (NCCH) in Japan. One research article by the Department of Thoracic Surgery was selected as a keynote presentation.
From May 25 to 27, the 33rd Meeting of the European Society of Thoracic Surgery (ESTS 2025) was held in Budapest, Hungary. The Department of Thoracic Surgery delivered an outstanding performance and achieved remarkable results—receiving an international award, delivering a debut presentation on the prestigious Brompton Session, and having multiple posters accepted for presentation.
33 Radiotherapy Center Showcases Multiple Research Results at ESTRO 2025
From May 2 to 6, the Congress of the European Society for Radiotherapy and Oncology (ESTRO) 2025 was held in Vienna, Austria. Two research articles by the Radiotherapy Center were selected for oral presentation at the congress and four for poster presentation.
34 Gynecologic Oncology Center Hosts Patient Education Event on the 13th World Ovarian Cancer Day
On May 8, the Gynecologic Oncology Center hosted a patient education event themed “Caring for Women and Safeguarding Health” in observance of the 13th World Ovarian Cancer Day.
35 Head and Neck Surgery Team Launches Smart Educational Platform for Thyroid-Head and Neck Cancers
On May 10, at the 11th Annual Meeting of the Committee of Otolaryngology-Head and Neck Surgery of the Chinese Medical Doctor Association, Professor Li Chao’s team from the Head and Neck Surgery of SCH announced the launch of the Smart Educational Platform for Thyroid-Head and Neck Cancers—Thyroid-Head and Neck AI Assistant.
36 SCH Hosts Series of Events to Celebrate International Nurses Day
On May 12, SCH hosted a celebration of International Nurses Day in the International Academic Hall. On behalf of SCH’s CPC and administration leadership, SCH Director Lin Tongyu extended his heartfelt gratitude and reverence to all nursing staff for their dedication and hard work. The celebration featured the presentation of the “Most Outstanding Nurses with 30 Years of Service” award, the capping ceremony for newly recruited nurses, the Nightingale Pledge, and a variety of performances from hospital departments.
Additionally, SCH hosted a series of thematic activities throughout May, including a Humanistic Nursing Model Ward Competition, a Nursing Professionalism Short Video Challenge, and a Creative Nurse Market Fair.
37 Delegation from the Islands Healthcare Complex—Macao Medical Center of Peking Union Medical College Hospital Visits SCH
On May 15, a five-member delegation, led by Li Jun, Deputy Director of the Islands Healthcare Complex—Macao Medical Center of Peking Union Medical College Hospital, visited SCH for exchanges on hospital operation and administration, optimization of medical services, and other topics. SCH Director Lin Tongyu and Chief Accountant Li Jian, along with heads of the Finance Division, Operations and Development Division, and Tianfu Branch Administration Office, attended the event and a symposium with the delegation.
38 SCH’s Research on Thyroid Cancer Published in Q1 Journal
Recently, postdoctoral fellow Zhang Sicheng from Professor Li Chao’s research team of SCH published a research paper titled “Tetrahedral DNA Nanostructure Based siRNA Delivery Vehicle for BRAF Gene Silencing and MEK-ERK Pathway Inhibition in the Treatment of Refractory Thyroid Cancer” in Nano Today (IF: 13.2), a Q1 journal in the JCR ranking. The paper is the first to introduce a high-efficiency TDN-siBraf delivery system with prolonged siRNA half-life and enhanced antitumor activity in refractory thyroid cancer, offering a promising strategy with significant clinical translation potential.
39 Department of Pathology and Anesthesiology Medical Center Approved as 2025 Provincial-Level Key Clinical Specialty Development Projects
On May 26, the Health Commission of Sichuan Province officially released Implementation Plan for 2025 Sichuan Provincial-Level Key Clinical Specialty Development Projects. The Department of Pathology and the Anesthesiology Medical Center were successfully included as 2025 provincial-level key clinical specialty development projects. Currently, SCH boasts 4 national-level key clinical specialties, 8 provincial-level key clinical specialties, and 14 provincial-level key medical disciplines (laboratories).
40 “Star Library—Children’s Caring Reading Space Joint Establishment Program” Inaugurated and Put into Operation in Ward of Department of Pediatric Oncology at SCH
On May 27, the third installment of “Xingxing Library—Children’s Caring Reading Space Joint Establishment Program”, jointly initiated by Chuanguan News, Sichuan Provincial Charity Federation, and SCH, was inaugurated and put into operation in the ward of the Department of Pediatric Oncology of SCH. The event garnered extensive support from various sectors of the society, with hundreds of devoted readers contributing to its joint establishment. Prior to the International Children’s Day, the program presented a special gift to the children undergoing inpatient treatment at SCH.
